Citations Appearing in 2013

  1. Babafemi Taiwo, M., P. Edward P. Acosta, M. Patrick Ryscavage, M. Baiba Berzins, P. Darlene Lu, Jay Lalezari, MD,, M. Jose Castro, Oluwatoyin Adeyemi, MD,#, . . .and M. and Susan Swindells. Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study. Clinical Science 64(2): 167-173, 2013.
  2. Baek, I.-H., B.-Y. Lee, M.-S. Kim and K.-I. Kwon. Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs. Xenobiotica 43(10): 895-900, 2013.
  3. Baek, I.-H., B.-Y. Lee, M.-S. Kim and K.-I. Kwon. Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs. European Journal of Drug Metabolism and Pharmacokinetics: 1-5, 2013.
  4. Bauer, R.J., G. Mo and W. Krzyzanski. Solving delay differential equations in S-ADAPT by method of steps. Computer Methods and Programs in Biomedicine 111(3): 715-734, 2013.
  5. Bhalodi, A.A., P.K. Papasavas, D.S. Tishler, D.P. Nicolau and J.L. Kuti. Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults. Antimicrobial Agents and Chemotherapy 57(3): 1144-1149, 2013.
  6. Black, L.A., C.B. Landersdorfer, J.B. Bulitta, J.E. Griffith and M. Govendir. Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. Journal of Veterinary Pharmacology and Therapeutics 37(3): 301-311, 2013.
  7. Blaney, S.M., M. Tagen, A. Onar-Thomas, S.L. Berg, S. Gururangan, K. Scorsone, . . .and C. Stewart. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a pediatric brain tumor consortium study. Pediatric Blood & Cancer 60(4): 627-632, 2013.
  8. Buitrago, E., M.J. Del Sole, A. Torbidoni, A. Fandino, M. Asprea, J.O. Croxatto, . . .and P. Schaiquevich. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Experimental Eye Research 108: 103-109, 2013.
  9. Bulitta, J.B., O.O. Okusanya, A. Forrest, S.M. Bhavnani, K. Clark, J.G. Still, . . .and P.G. Ambrose. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial Agents and Chemotherapy 57(1): 498-507, 2013.
  10. Butterfield, J.M., T.P. Lodise, S. Beegle, J. Rosen, J. Farkas and M.P. Pai. Pharmacokinetics and Pharmacodynamics of Once-Daily Administration of Intravenous Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary Exacerbation. Antimicrobial Agents and Chemotherapy 57(10): 5175-5177, 2013.
  11. Butterfield, J.M., B.A. Mueller, N. Patel, K.E. Cardone, D.W. Grabe, N.N. Salama and T.P. Lodise. Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis. Antimicrobial Agents and Chemotherapy 57(2): 864-872, 2013.
  12. Caliph, S.M., E. Cao, J.B. Bulitta, L. Hu, S. Han, C.J.H. Porter and N.L. Trevaskis. The impact of lymphatic transport on the systemic disposition of lipophilic drugs. Journal of Pharmaceutical Sciences 102(7): 2395-2408, 2013.
  13. Camaione, L., K. Elliott, A. Mitchell-Van Steele, B. Lomaestro and M.P. Pai. Vancomycin Dosing in Children and Young Adults: Back to the Drawing Board. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33(12): 1278-1287, 2013.
  14. Cao, Y., J. Balthasar and W. Jusko. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics: (40)5: 597-607, 2013.
  15. Chae, J.-W., J.-w. Seo, B. Mahat, H.-y. Yun, I.-h. Baek, B.-y. Lee, . . .and K.-i. Kwon. A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Development and Industrial Pharmacy (0): 1-5, 2013.
  16. Chen, T., L. Kagan and D.E. Mager. Population Pharmacodynamic Modeling of Exenatide After 2-Week Treatment in STZ/NA Diabetic Rats. Journal of Pharmaceutical Sciences 102(10): 3844-3851, 2013.
  17. Conversy B., M.C. Blais, M. Dunn, C. Gara-Boivin, L. Carioto L and J.R.E. del Castillo. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma. The Veterinary Journal 198(2):437-443, 2013.
  18. Corinne Seng Yue1-2, K.G., L.L. and M.P.D. . Novel Population Pharmacokinetic Method Compared to the Standard Noncompartmental Approach to Assess Bioequivalence of Iron Gluconate Formulations Journal of Pharmacy & Pharmaceutical Sciences 16(3): 424 – 440, 2013.
  19. Dahlberg, A.M., L.M. Kaminskas, A. Smith, J.A. Nicolazzo, C.J.H. Porter, J.B. Bulitta and M.P. McIntosh. The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. Molecular Pharmaceutics 11(2): 496-504, 2013.
  20. Eckmann, K., L.B. Michaud, E. Rivera, T.L. Madden, L. Esparza-Guerra, J. Kawedia, . . .and V. Valero. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Journal of Oncology Pharmacy Practice 20(20): 120-129, 2013.
  21. Falcone, M., A. Russo, M. Venditti, A. Novelli and M.P. Pai. Considerations for Higher Doses of Daptomycin in Critically Ill Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases, 57(11): 1568-1576, 2013.
  22. Felton, T.W., J. Goodwin, L. O’Connor, A. Sharp, L. Gregson, J. Livermore, . . .and W.W. Hope. Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 57(12), 2013.
  23. Fetterly, G., U. Aras, D. Lal, M. Murphy, P. Meholick and E. Wang. Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia. The AAPS Journal 15(3): 662-673, 2013.
  24. Fetterly, G.J., U. Aras, P.D. Meholick, C. Takimoto, S. Seetharam, T. McIntosh, . . .and T.A. Puchalski. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. The Journal of Clinical Pharmacology 53(10): 1020-1027, 2013.
  25. Fischer, J., G. Sarto, J. Hardman, L. Endres, T. Jenkins, S. Kilpatrick, . . .and K. Rodvold. Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy. Clinical Pharmacokinetics 53(4): 373-383, 2013.
  26. Fruit, D., A. Rousseau, C. Amrein, F. Rollé, N. Kamar, L. Sebbag, . . .and A. Prémaud. Ciclosporin Population Pharmacokinetics and Bayesian Estimation in Thoracic Transplant Recipients. Clinical Pharmacokinetics 52(4): 277-288, 2013.
  27. Fukuda, Y., K. Takenaka, A. Sparreboom, S.B. Cheepala, C.-P. Wu, S. Ekins, . . .and J.D. Schuetz. Human Immunodeficiency Virus Protease Inhibitors Interact with ATP Binding Cassette Transporter 4/Multidrug Resistance Protein 4: A Basis for Unanticipated Enhanced Cytotoxicity. Molecular Pharmacology 84(3): 361-371, 2013.
  28. Gramatica, P. (2013). On the Development and Validation of QSAR Models. Computational Toxicology. B. Reisfeld and A. N. Mayeno, Humana Press. 930: 499-526.
  29. Guiastrennec, B., L. Wollenberg, A. Forrest and S. Ait-Oudhia. AMGET, an R-Based Postprocessing Tool for ADAPT 5. CPT: pharmacomet. syst. pharmacol. 2(e61), 2013.
  30. Guillaumie, L., G. Godin, J.-C. Manderscheid, E. Spitz and L. Muller. Self-efficacy and implementation intentions-based interventions on fruit and vegetable intake among adults: impact at 12-month follow-up. Global Health Promotion 20(2 suppl): 83-87, 2013.
  31. Haddish-Berhane, N., D. Shah, D. Ma, M. Leal, H.-P. Gerber, P. Sapra, . . .and A. Betts. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Journal of Pharmacokinetics and Pharmacodynamics: (40)5: 557-571, 2013.
  32. Hall, R.G., M.A. Swancutt, C. Meek, R. Leff and T. Gumbo. Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures Beyond 2/3 or ¾. Antimicrobial Agents and Chemotherapy 57(5): 2259-2264, 2013.
  33. Hamed, S., R. Straubinger and W. Jusko. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemotherapy and Pharmacology 72(3): 553-563, 2013.
  34. Hamilton, R., X.C. Thai, D. Ameri and M.P. Pai. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? Journal of Antimicrobial Chemotherapy 68(3): 666-673, 2013.
  35. Hao, K., Q. Qi, H. Hao, G. Wang, Y. Chen, Y. Liang and L. Xie. The Pharmacokinetic-Pharmacodynamic Model of Azithromycin for Lipopolysaccharide-Induced Depressive-Like Behavior in Mice. PLoS ONE 8(1): e54981, 2013.
  36. Jain, M.K., J.G. Pasipanodya, L. Alder, W.M. Lee and T. Gumbo. Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy 57(3): 1115-1120, 2013.
  37. Jiang, X.-L., H.-W. Shen, D.E. Mager and A.-M. Yu. Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. Drug Metabolism and Disposition 41(5): 975-986, 2013.
  38. Kebriaei, P., T. Madden, X. Wang, P.F. Thall, C. Ledesma, M. de Lima, . . .and B.S. Andersson. Intravenous busulfan plus melphalan: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48: 26-31, 2013.
  39. Koch, G. and J. Schropp. Solution and implementation of distributed lifespan models. Journal of Pharmacokinetics and Pharmacodynamics 40(6): 639-650, 2013.
  40. Landersdorfer, C.B., N.S. Ly, H. Xu, B.T. Tsuji and J.B. Bulitta. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrobial Agents and Chemotherapy 57(5): 2343-2351, 2013.
  41. Li, Y., T. Zhang, X. Li, P. Zou, S.J. Schwartz and D. Sun. Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. Molecular Nutrition & Food Research 57(12): 2128-2136, 2013.
  42. Lin, S., N.A. Page, S.M. Fung and H.-L. Fung. In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1. Nitric Oxide 35(0): 137-143, 2013.
  43. Liu, D.-Y., H.-K. Lon, Y.-L. Wang, D.C. DuBois, R.R. Almon and W.J. Jusko. Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. Biopharmaceutics & Drug Disposition 34(4): 203-214, 2013.
  44. Livermore, J.L., T.W. Felton, J. Abbott, A. Sharp, J. Goodwin, L. Gregson, . . .and W.W. Hope. Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. Antimicrobial Agents and Chemotherapy 57(1): 281-288, 2013.
  45. Louie, A., W. Liu, S. Fikes, D. Brown and G.L. Drusano. Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa Pneumonia. Antimicrobial Agents and Chemotherapy 57(6): 2788-2792, 2013.
  46. Louie, A., B. VanScoy, W. Liu, R. Kulawy and G.L. Drusano. Hollow-Fiber Pharmacodynamic Studies and Mathematical Modeling To Predict the Efficacy of Amoxicillin for Anthrax Postexposure Prophylaxis in Pregnant Women and Children. Antimicrobial Agents and Chemotherapy 57(12): 5946-5960, 2013.
  47. MacDonald, T.J., G. Vezina, C.F. Stewart, D. Turner, C.R. Pierson, L. Chen, . . .and M.W. Kieran. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-Oncology, 15(10): 1438-1444, 2013.
  48. Mandelli, D., A. Yilmaz, T. Aldemir, K. Metzroth and R. Denning. Scenario clustering and dynamic probabilistic risk assessment. Reliability Engineering & System Safety 115: 146-160, 2013.
  49. Muscal, J., K. Scorsone, L. Zhang, J. Ecsedy and S. Berg. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Investigational New Drugs 31: 39-45, 2013.
  50. Muscal, J.A., P.A. Thompson, T.M. Horton, A.M. Ingle, C.H. Ahern, R.M. McGovern, . . .and S.M. Blaney. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a children’s oncology group phase I consortium study (ADVL0916). Pediatric Blood & Cancer 60(3): 390-395, 2013.
  51. Musuka, S., S. Srivastava, C.W. Siyambalapitiyage Dona, C. Meek, R. Leff, J. Pasipanodya and T. Gumbo. Thioridazine Exhibits Wobbly Pharmacokinetic-Pharmacodynamic Parameters During Treatment of Tuberculosis: A Theoretical Basis for Shorter Duration Curative Monotherapy with Congeners. Antimicrobial Agents and Chemotherapy 57(12): 5870-5877, 2013.
  52. New, L., T. Lim, J. Oh, G. Cheah, A. Kwa and E. Chan. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin. Analytical and Bioanalytical Chemistry 405(4): 1407-1415, 2013.
  53. Ng, C.M. Novel Hybrid GPU–CPU Implementation of Parallelized Monte Carlo Parametric Expectation Maximization Estimation Method for Population Pharmacokinetic Data Analysis. The AAPS Journal 15(4): 1212-1221, 2013.
  54. Ng, C.M., K.M. Loyet, S. Iyer, P.J. Fielder and R. Deng. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. European Journal of Pharmaceutical Sciences 2860(0): 8, 2013.
  55. O’Connor, L., J. Livermore, A.D. Sharp, J. Goodwin, L. Gregson, S.J. Howard, . . .and W.W. Hope. Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. Journal of Infectious Diseases 208(2): 351-361, 2013.
  56. Pai, M.P. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. Journal of Antimicrobial Chemotherapy, 69(1): 190-199, 2013.
  57. Parise, R., B. Anyang, J. Eiseman, M. Egorin, J. Covey and J. Beumer. Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines. Cancer Chemotherapy and Pharmacology 71: 73-83, 2013.
  58. Pasipanodya, J.G., H. McIlleron, A. Burger, P.A. Wash, P. Smith and T. Gumbo. Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes. Journal of Infectious Diseases 208(9): 1464-473, 2013.
  59. Patel, K., K.T. Batty, B.R. Moore, P.L. Gibbons, J.B. Bulitta and C.M. Kirkpatrick. Mechanism-Based Model of Parasite Growth and Dihydroartemisinin Pharmacodynamics in Murine Malaria. Antimicrobial Agents and Chemotherapy 57(1): 508-516, 2013.
  60. Pauley, J., J. Panetta, K. Crews, D. Pei, C. Cheng, J. McCormick, . . .and M. Relling. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology 72(2): 369-378, 2013.
  61. Pawaskar, D., R. Straubinger, G. Fetterly, B. Hylander, E. Repasky, W. Ma and W. Jusko. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemotherapy and Pharmacology 71(5): 1219-1229, 2013.
  62. Pawaskar, D., R. Straubinger, G. Fetterly, W. Ma and W. Jusko. Interactions of everolimus and sorafenib in pancreatic cancer cells. The American Association of Pharmaceutical Scientists Journal 15(1): 78-84, 2013.
  63. Perera, V., A.S. Gross, A. Forrest, C.B. Landersdorfer, H. Xu, S. Ait-Oudhia and A.J. McLachlan. Investigating the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 activity: A Pharmacodynamic Driven Change in Pharmacokinetics? Drug Metabolism and Disposition, 41(11): 1957-1966, 2013.
  64. Rao, G.G., N.S. Ly, C.E. Haas, S. Garonzik, A. Forrest, J.B. Bulitta, . . .and B.T. Tsuji. New Dosing Strategies for an ‘Old’ Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics of Patients with Kidney or Liver Disease. Antimicrobial Agents and Chemotherapy, 58(3): 1381-1388 2013.
  65. Roberts, M.S., D.C. Turner, T.S. Owens, A. Ramachandran, C. Wetmore, S.L. Throm and C.F. Stewart. Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography–electrospray ionization-tandem mass spectrometry (LC–ESI-MS/MS). Journal of Chromatography B 929(0): 1-5, 2013.
  66. Ryan, G.M., L.M. Kaminskas, J.B. Bulitta, M.P. McIntosh, D.J. Owen and C.J.H. Porter. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release 172(1): 128-136, 2013.
  67. Sandri, A.M., C.B. Landersdorfer, J. Jacob, M.M. Boniatti, M.G. Dalarosa, D.R. Falci, . . .and A.P. Zavascki. Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clinical Infectious Diseases, 57(4): 524-531, 2013.
  68. Schneck, K., X. Zhang, R. Bauer, M. Karlsson and V. Sinha. Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. Journal of Pharmacokinetics and Pharmacodynamics 40(1): 67-80, 2013.
  69. Shah, D. and J. Balthasar. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. Journal of Pharmacokinetics and Pharmacodynamics: 41(1): 55-69, 2013.
  70. Skrobik, Y. and M. Laverdiere. Why Candida Sepsis Should Matter to ICU Physicians. Critical Care Clinics 29(4): 853-864, 2013.
  71. Soon, R.L., N.S. Ly, G. Rao, L. Wollenberg, K. Yang, B. Tsuji and A. Forrest. Pharmacodynamic variability beyond that explained by MICs. Antimicrobial Agents and Chemotherapy 57(4): 1730-1735, 2013.
  72. Soon, R.L., S.J. Turner, A. Forrest, B.T. Tsuji and J. Brown. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. International Journal of Antimicrobial Agents 42(1): 53-58, 2013.
  73. Staschen, C.-M. and I. Mahmood. A population pharmacokinetic model of remifentanil in pediatric patients using body-weight-dependent allometric exponents. Drug metabolism and drug interactions 28(4): 231-237, 2013.
  74. Stepensky, D. Prediction of Drug Disposition on the Basis of its Chemical Structure. Clinical Pharmacokinetics 52(6): 415-431, 2013.
  75. Sudan, A., J. Livermore, S.J. Howard, Z. Al-Nakeeb, A. Sharp, J. Goodwin, . . .and W.W. Hope. Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints. Antimicrobial Agents and Chemotherapy 57(6): 2793-2800, 2013.
  76. Tatarinova, T., M. Neely, J. Bartroff, M. Guilder, W. Yamada, D. Bayard, . . .and A. Schumitzky. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. Journal of Pharmacokinetics and Pharmacodynamics 40(2): 189-199, 2013.
  77. Trevaskis, N., S. Caliph, G. Nguyen, P. Tso, W. Charman and C.H. Porter. A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport. Pharmaceutical Research: 30(12): 3254-3270, 2013.
  78. Venci, J., M. Rowcliffe, L. Wollenberg, M. Rainka and F. Gengo. Pharmacokinetic simulation of fatal carbamazepine intoxication in 23-month old child following phenytoin discontinuation. Forensic Science, Medicine, and Pathology 9: 73-76, 2013.
  79. W. S. Yapa, S., J. Li, C.J.H. Porter, R.L. Nation, K. Patel and M.P. McIntosh. Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections. Antimicrobial Agents and Chemotherapy 57(10): 5087-5095, 2013.
  80. Weiss, M., X. Liu, C.A. Thorling and M.S. Roberts. Functional characterization of hepatic transporters using intravital microscopy. European Journal of Pharmaceutical Sciences 49(5): 845-849, 2013.
  81. Zhang, T., Y. Li, P. Zou, J.-y. Yu, D. McEachern, S. Wang and D. Sun. Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharmaceutics & Drug Disposition 34(6): 348-359, 2013.
  82. Zhou, A., G. Pacini, B. Ahrén and D. D’Argenio. Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia: 57(4): 801-808, 2013.
  83. Zhu, R., Y. Zheng, W. Putnam, J. Visich, M. Eisner, J. Matthews, . . .and D. D’Argenio. Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy. The AAPS Journal 15(2): 559-570, 2013.